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Many  enzymes  catalyse  reactions  that  have  an  oestrogen  as a substrate  and/or  a product.  The  reac-
tions  catalysed  include  aromatisation,  oxidation,  reduction,  sulfonation,  desulfonation,  hydroxylation
and  methoxylation.  The  enzymes  that  catalyse  these  reactions  must  all  recognise  and bind  oestrogen  but,
despite this,  they  have  diverse  structures.  This review  looks  at each  of  these  enzymes  in turn,  describing
the  structure  and  discussing  the mechanism  of the  catalysed  reaction.  Since  oestrogen  has a  role  in  many
disease  states  inhibition  of the  enzymes  of oestrogen  metabolism  may  have  an  impact  on  the  state  or
progression  of the  disease  and  inhibitors  of  these  enzymes  are  brieﬂy  discussed.estrogen
rotein structure
eaction mechanism
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1. Introduction
Estrogens have many roles in the body including, but not limited
to, in reproduction and the menstrual cycle [1–5], many breast can-
cers [6], the development of osteoarthritis [7], the prevention of
heart disease [8], neuroprotection during cerebral ischaemia [9]
and in multiple sclerosis [10], appetite and eating behaviour [11],
fat metabolism [12], schizophrenia [13], autoimmunity [14], and
auditory and visual processing [15]. Estrogens exert their effects in
several ways [16–18]. In the ‘classic genome response’ oestrogen
binds to speciﬁc intracellular oestrogen receptors (ER and ER)
that, subsequent to oestrogen binding, dimerise and translocate to
the nucleus, where they modulate the transcription of target genes
that contain oestrogen-responsive elements in their promoters.
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owever, these same oestrogen receptors have also been shown (a)
o bind to other transcription factors thus inﬂuencing the expres-
ion of genes that do not contain oestrogen-responsive elements
n their promoters, and (b) to engage signal transduction pathways
that may  include, but are not limited to, the activation of protein
inases), thus modulating cellular responses to oestrogen. Signal
ransduction pathways can also be activated by oestrogen binding
o cell surface membrane bound receptors [16–18].
The three most common estrogens are estrone (E1), estradiol
E2) and estriol (E3). A fourth oestrogen is estetrol (E4). Estradiol
s the most potent. Estrone and estradiol are synthesised by the
romatisation of androstenedione and testosterone, respectively
Fig. 1). They can also be interconverted by the action of 17-
ydroxysteroid dehydrogenases (17-HSDs). Estriol is synthesised
rom estrone via a 16-hydroxyestrone intermediate. Although, in
ome tissues, estrogens can be made on demand, oestrogen can
e stored in the form of estrone sulfate. This is synthesised from
strone by the action of oestrogen sulfotransferase with estrone
eing regenerated by the steroid sulfatase-catalysed hydrolysis
f estrone sulfate. A review of many aspects of human steroido-
enesis is available [19]. Estrogens are eliminated from the body
ainly as the sulfated and glucuronidated derivatives [20, and
ig. 1. Pathways of oestrogen metabolism. Not all pathways are shown. There are tis
ompounds are converted to the methoxy compounds by catechol O-methyltransferase
abelling and atom numbering system.mistry & Molecular Biology 137 (2013) 27– 49
references therein]. The ﬁrst step in synthesising these conjugates
is the generation of the hydroxylated derivatives. Hydroxylation
occurs primarily at the 2-, 4- and 16-positions. The hydroxyl group
can then be sulfated, glucuronidated or methylated.
Because there is little published work on estetrol it is discussed
only brieﬂy here. It is synthesised in the foetal liver, but its func-
tion is presently unknown. Several possible biosynthetic routes
have been proposed starting from various androgens, estrogens,
and their 3-sulfated derivatives, with the hydroxylations occurring
in various different orders and, in the case of the androgens, the
aromatisation occurring either before or after the hydroxylations.
Evidence suggests that estetrol is made through multiple biosyn-
thetic routes. See [21–29] for details. Estetrol will not be discussed
further herein.
Given the role of estrogens in preventing, causing and exacer-
bating disease a good knowledge of how estrogens are synthesised
and metabolised may  help in the understanding and treatment of
disease. This review looks in turn at each of the enzymes involved
in oestrogen metabolism in terms of their structure and reaction
mechanism, before a ﬁnal section compares the various enzymes.
Inhibition of the enzymes of oestrogen metabolism impacts on the
amount of oestrogen in the body and this has been the subject of
sue-speciﬁc variations in synthetic pathways: see [19]. The A-ring hydroxylated
s. The structures of estetrol and ethinylestradiol are shown, as is the steroid ring
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fFig. 2. (A) The reactions catalysed by oestrogen sul
ultiple therapeutic approaches leading to clinically active agents
30,31]. Also, synthetic estrogens, e.g.,  ethinylestradiol (Fig. 1),
ave been widely employed in hormone replacement therapy [32]
nd, combined with a progestin, contraception [33,34]. Although
nhibitors of these enzymes and synthetic estrogens are not the
ocus of this review they are brieﬂy discussed, mainly through ref-
rences to recent reviews. Unless otherwise stated, all discussions
elow refer to the human enzymes.
. Methods
All dockings of ligands into binding sites were carried out
sing the GOLD software running in Gold Suite v5.0.1. All
ther manipulations of molecules, including building ligands and
reparing proteins for docking runs, were carried out using
he Schrödinger software running under Maestro 9.2.109. The
rotein crystal structures were downloaded from the PDB and
un through the Protein Preparation Wizard. Hydrogens were
dded assuming a neutral pH and the resulting structures were
ut through a brief minimisation procedure. Visual inspection
f these structures was used to identify those residues that
orm substrate binding sites. All ﬁgures of proteins and ligandssferase. (B) The cofactor, before and after reaction.
were prepared using PyMOL (Delano Scientiﬁc). Figures of reac-
tion schemes and molecules were prepared using ChemBioDraw
Ultra 12.0. Multalin was used to perform sequence alignments
(http://multalin.toulouse.inra.fr/multalin/multalin.html).
3. Oestrogen sulfotransferase
Oestrogen sulfotransferase (EC 2.8.2.4, SULT1E1) is a cyto-
solic enzyme that catalyzes the sulfonation of estrogens, utilising
3′-phosphoadenosine-5′-phosphosulfate (PAPS) as the sulfate-
donating cofactor [35,36] (Fig. 2). This enzyme has a high afﬁnity
for estrogens with maximal activity at about Km = 20 nM [37].
There are two other sulfotransferases in the SULT1 class that catal-
yse the sulfonation of estrogens: SULT1A1 and SULT1A3 (both EC
2.8.2.1, phenol sulfotransferase). However, these enzymes have
much lower afﬁnities for estrogens, with maximal activity at about
Km = 25 M.  For all three human proteins the amino acid sequence
is available, as is that of murine SULT1E1 (Fig. 3): SULT1A1 and
SULT1A3 are 92.5% identical, and both are approximately 50% iden-
tical to SULT1E1. The sequence of murine SULT1E1 is 75% identical
to that of the human protein.
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                  <-H0-->  <Sa>  <Sb  ><--H1/H2- -->        <-Sc>
SULT  1E1     1  MNSELDYYEK –FEEVHGILM  YKDFVKYWDN VEAFQARPDD  LVIATYPKSG   49
SULT 1E1    1  METSMPEYYE VFGEFRGVLM DKRFTKYWED VEMFLARPDD LVIATYPKSG   50
SULT  1A1     1  MELIQDTSRP PLEYVKGVPL  IKYFAEALGP LQSFQARPDD  LLISTYPKSG   50
SULT  1A3     1  MELIQDTSRP PLEYVKGVPL  IKYFAEALGP LQSFQARPDD  LLINTYPKSG   50
               <-----H3-- -->   <-H4 >   <H5> < -Loop-1-->  <--H6->
SULT 1E1   50  TTWVSEIVYM IYKEGDVEKC KEDVIFNRIP FLECRKENLM NGVKQLDEMN   99
SULT  1E1    51  TTWISEVVYM IYKEGDVEKC  KEDAIFNRIP YLECRNEDLI  NGIKQLKEKE  100
SULT  1A1    51  TTWVSQILDM IYQGGDLEKC  HRAPIFMRVP FLEFKAPGIP  SGMETLKDTP  100
SULT  1A3    51  TTWVSQILDM IYQGGDLEKC  NRAPIYVRVP FLEVNDPGEP  SGLETLKDTP  100
                 <-Sd>         <-H7- >   <-Se>   <------H8 ----><Loop
SULT  1E1   100  SPRIVKTHLP PELLPASFWE  KDCKIIYLCR NAKDVAVSFY  YFFLMVAGHP  149
SULT  1E1   101  SPRIVKTHLP PKLLPASFWE  KNCKMIYLCR NAKDVAVSYY  YFLLMITSYP  150
SULT  1A1   101  APRLLKTHLP LALLPQTLLD  QKVKVVYVAR NAKDVAVSYY  HFYHMAKVHP  150
SULT  1A3   101  PPRLIKSHLP LALLPQTLLD  QKVKVVYVAR NPKDVAVSYY  HFHRMEKAHP  150
               -2> <---H9  --->        <-H10/H11  --->   <Sf ><-H12->  <
SULT  1E1   150  NPGSFPEFVE KFMQGQVPYG  SWYKHVKSWW EKGKSPRVLF  LFYEDLKEDI  199
SULT  1E1   151  NPKSFSEFVE KFMQGQVPYG  SWYDHVKAWW EKSKNSRVLF  MFYEDMKEDI  200
SULT  1A1   151  EPGTWDSFLE KFMVGEVSYG  SWYQHVQEWW ELSRTHPVLY  LFYEDMKENP  200
SULT  1A3   151  EPGTWDSFLE KFMAGEVSYG  SWYQHVQEWW ELSRTHPVLY  LFYEDMKENP  200
               ----H13---  >     <--- H14---> <-  H15>  <-----Loop-3---
SULT  1E1   200  RKEVIKLIHF LERKPSEELV  DRIIHHTSFQ EMKNNPSTNY  TTLPDEIMNQ  249
SULT  1E1   201  RREVVKLIEF LERKPSAELV  DRIIQHTSFQ EMKNNPSTNY  TMMPEEMMNQ  250
SULT  1A1   201  KREIQKILEF VGRSLPEETV  DFVVQHTSFK EMKKNPMTNY  TTVPQEFMDH  250
SULT  1A3   201  KREIQKILEF VGRSLPEETM  DFMVQHTSFK EMKKNPMTNY  TTVPQELMDH  250
               -Loop-3-->   <H16>  < -----H17-- --->
SULT  1E1   250  KLSPFMRKGI TGDWKNHFTV  ALNEKFDKHY EQQMKESTLK  FRTEI        294
SULT  1E1   251  KVSPFMRKGI IGDWKNHFPE  ALRERFDEHY KQQMKDCTVK  FRMEL        295
SULT  1A1   251  SISPFMRKGM AGDWKTTFTV  AQNERFDADY AEKMAGCSLS  FRSEL        295
SULT  1A3   251  SISPFMRKGM AGDWKTTFTV  AQNERFDADY AEKMAGCSLS  FRSEL        295
Fig. 3. Sequences of sulfotransferases. Human SULT1E1 (oestrogen sulfotransferase) UniProt P49888. Murine SULT1E1 (oestrogen sulfotransferase) UniProt P49891. Human
S trans
i . Secon
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oULT1A1 (phenol sulfotransferase) UniProt P50225. Human SULT1A3 (phenol sulfo
n  yellow. Other residues identical to the human SULT 1E1 are highlighted in cyan
tructure of human SULT1E1, are shown in bold: the numbering of these elements 
Available from the PDB are two crystal structures of human
ULT1E1, three of murine SULT1E1, two of human SULT1A3, and
ight of human SULT1A1 (Table 1). Given the high level of sequence
dentity it is not surprising that the three-dimensional structures
re superimposable. The protein is a single domain globular struc-
ure (Fig. 4).Thirty-one crystal structures of twelve different human sulfo-
ransferases have been the subject of a recent review [48] that
overs substrate speciﬁcity and mechanisms of action. An older
able 1
he crystal structures of sulfotransferases. The mutations are all remote from the substra
r  catalysis.
Protein PDB code Ligands 
Human 1E1 1HY3 PAPS 
1G3M PAP, polychlorinated bip
Murine 1AQU PAP, estradiol 
1AQY PAP 
1BO6 PAP, vanadate 
Human 1A1 1LS6 PAP, p-nitrophenol 
1Z28 PAP 
2D06 PAP, estradiol 
3U3J PAP 
3U3K PAP, naphthalene-2-ol 
3U3M PAP, 3-cyano-7-hydroxy
3U3O PAP, 3-cyano-7-hydroxy
3U3R PAP, p-nitrophenol 
Human 1A3 1CJM Sulphate 
2A3R PAP, dopamine ferase) UniProt P50224. Residues identical across all four proteins are highlighted
dary structural elements, as identiﬁed by PyMOL (Delano Scientiﬁc) in the 1G3M
istent with that of [49]. H – helix, S – sheet.
review covering sulfotransferase structure and inhibitors is avail-
able [49].
Fig. 5 shows the structure of the binding site of human SULT1E1.
To generate Fig. 5A the reaction product was docked into the 1HY3
structure after the sulfate had been removed from the cofactor.
To generate Fig. 5B the substrate was  docked into the 1HY3 struc-
ture. In both instances, subsequent to docking, the protein ligand
complex was  put through 1000 rounds of minimisation prior to
preparing the ﬁgures. A comparison of the two structures (Fig. 5C)
te and cofactor binding sites and are not expected to have any inﬂuence on binding
Mutations Reference
V269E [38]
henol – [39]
– [40]
– [40]
– [41]
– [46]
– [45]
– [44]
R213H, V223M [47]
R213H, V223M [47]
coumarin R213H, V223M [47]
coumarin R213H, V223M [47]
R213H, V223M, D249G [47]
– [42]
– [43]
M.P. Thomas, B.V.L. Potter / Journal of Steroid Biochem
Fig. 4. The three-dimensional structure of oestrogen sulfotransferase. The 1G3M
(SULT1E1) structure [39] is shown. The cofactor PAPS (purple carbons) is taken from
the 1HY3 structure [38], and the steroid (pink carbons) is from the 2D06 structure
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d44]. The helices, H0-H17 are identiﬁed, as are the sheets Sa-Sd. Sheets Se and Sf are
idden behind H3, H11 and H15. The ﬂexible loops involved in binding the substrate
nd cofactor are identiﬁed thus: Loop 1, purple; Loop 2, brown; Loop 3, dark blue.
hows that three of the water molecules have different positions
ut the ligand moves only slightly, and the surrounding residues
arely move at all.
The substrate and cofactor binding site takes the form of a
ube, open at both ends, running through the core of the protein.
he residues forming the substrate binding site are predominantly
ydrophobic and enclose the substrate quite closely. These residues
Y20, F23, P46, F75, F80, C83, K85, M89, K105, H107, F138, F141,
145, A146, G147, H148, Y168, Y239, L242, I246 and M247) are
ainly from the three ﬂexible loops (Fig. 4), loop 1 (between helices
 and 6), loop 2 (between helices 8 and 9), and loop 3 (between
elices 15 and 16), but also helices H1 and H8 and sheet Sd. A partic-
larly close interaction is that of the hydrogens attached to C6 and
7 in the B-ring with the face of the Y20 ring. The side chain of F141
oints directly at the A-ring of the substrate to have a face–edge
– interaction. K105 has a hydrogen bond to the oxygen at the
-position. These interactions position the substrate hydroxyl so
hat it can act as the acceptor in the sulfate transfer.
The cofactor is enclosed by nineteen residues (K47, S48, G49,
50, T51, W52, K105, H107, R129, S137, Y192, T226, F228, M231,
254, M255, R256, K257 and G258) that are predominantly in
elices 3, 8 and 15, and loop 3. The PAPS adenine moiety has a
ace–face – stacking interaction with W52  and hydrogen bonds
o Y192 and T226. The ribose-3-phosphate has hydrogen bond
nteractions with R129, K257, G258 and R256, and the 5-phosphate
ith G49 and T51. The sulfate is held in position by interaction with
47 and K105. There are four water molecules that may  play a role
n catalysis and/or that interact with the substrate or cofactor.
A comparison of all human sulfotransferase structures suggests
hat the binding of substrate and PAPS can occur in a random order,
nd that substrate binding may  be cooperative with prior cofactor
inding, but not vice versa [50]. It seems likely that loop 3 must
ove to enable both substrate and cofactor to bind. The ends ofhis loop (helices 15 and 16) are in the vicinity of the cofactor:
f the entire loop opens as if the ends of the loop act as a hinge
hen the prior binding of the cofactor may  position the remain-
er of the loop to more easily bind the substrate. This is supportedistry & Molecular Biology 137 (2013) 27– 49 31
by crystal structures of SULT1A1 in complex with PAP and sub-
strate where the binding site is very similar to that observed when
just PAP is bound [47]. (The conformation of this loop subsequent
to PAPS binding is also thought to inﬂuence substrate binding in
human SULT2A1 [51].) There are some reports that at high substrate
concentrations sulfotransferases, particularly SULT1A1, suffer from
substrate inhibition [46,50]. Whether this is of relevance in vivo is
undetermined.
Three conserved residues, K47, H107 and S137, are thought
to be involved in the reaction mechanism (Fig. 6) [38,52]. S137
forms a hydrogen bond to K47, thus preventing the side chain
nitrogen of K47 from interacting with the bridging oxygen. This pre-
vents PAPS hydrolysis. Upon substrate binding, the catalytic base
H107 abstracts a proton from the substrate hydroxyl, thus enabling
nucleophilic attack at the sulphur atom in PAPS. The consequent
accumulation of partial negative charge on the bridging oxygen of
PAPS disrupts the interaction between S137 and K47, thus enabling
K47 to interact with the 5′-phosphate. This assists in the disso-
ciation of the sulfyryl group and completes the catalytic reaction
cycle [52,53]. The sulfonation takes place via an in-line displace-
ment mechanism though whether the mechanism is associative
(SN2-like) or dissociative (SN1-like) is not yet clear [53,54].
4. Steroid sulfatase
Steroid sulfatase (EC 3.1.6.2, aryl sulfatase C, steryl-sulfatase)
catalyzes the conversion of estrone sulfate to estrone (Fig. 1), and
dehydroepiandrosterone sulfate (DHEAS) to dehydroepiandros-
terone (DHEA) (the reverse of the reaction shown in Fig. 2). The
protein is found in the lumen of the endoplasmic reticulum and,
in terms of tissue distribution, is probably ubiquitous at low levels,
with greater amounts in those tissues associated with reproduc-
tion. The biology of steroid sulfatase has been reviewed [55] as has
the role of steroid sulfatase in oestrogen metabolism [56].
The gene has been cloned and sequenced, the protein expressed
and puriﬁed [57,58] and shown to consist of 583 residues
(Fig. 7). The structure of the protein has been solved (PDB
code 1P49: [59]) and shown to have a globular head (approxi-
mately 65 A˚ × 50 A˚ × 45 A˚) and a hydrophobic tail about 40 A˚ long
(Fig. 8). This tail is embedded in the lumenal membrane of the
endoplasmic reticulum. The crystal structure shows that several
residues undergo post-translational glycosylation. Another post-
translational modiﬁcation is that of C75 to formylglycine (FG)
(Fig. 9) [60]. This is further modiﬁed, by hydration, to form the gem-
diol hydroxyformylglycine (HFG), though the resting state of the
enzyme appears to be hydroxyformylglycine sulfate (HFGS) with
the sulfate linked to the pro-(S) hydroxyl group.
Visual inspection of the structure shows that a number of hydro-
gen bonds help position the HFGS and, speciﬁcally, the side chain
in the binding site (Fig. 10). The HFGS backbone carbonyl may  be
involved in a hydrogen bond with the backbone NH of R79, and the
HFGS side chain hydroxyl may  form a hydrogen bond to the side
chain of K134 and H136. There are four or, possibly, ﬁve interactions
of the sulfate with the protein that may  serve to position the sulfate
during the reaction. The ﬁrst of these four is an internal hydrogen
bond from the HFGS backbone NH, and the other four involve the
side chains of H290, K134 and, possibly, K368. A calcium ion in the
binding site has an interaction with one of the HFGS sulfate oxy-
gens. The calcium ion also has charge–charge interactions with the
side chains of D35, D36, D342 and Q343. The substrate binding site
is formed by residues L74, HFGS75, R98, T99, G100, V101, L103,
L164, T165, L167, R168, V177, F178, T180, G181, H290, T291, H346,
E349, K368, N447, T484, H485, V486, F488 and C489.
One proposed mechanism for the steroid sulfatase-catalysed
reaction is shown in Fig. 11 [61]. In Step I FG75 is activated by
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Fig. 5. The binding site of oestrogen sulfotransferase. (A) Estrone sulfate (pink carbons) and 3′-phosphoadenosine-5′-phosphate (purple carbons) in the binding site. The red
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mpheres are the oxygen atoms of water molecules in the binding site. (B) Estrone (cy
ite.  The brown spheres are the oxygen atoms of water molecules in the binding site
eaction.
 water molecule to form the gem-diol. In step II the substrate
ulphur undergoes nucleophilic attack by the pro-(S) hydroxyl fol-
owing its activation by Ca2+. This results in the sulfate moiety being
ovalently linked to FG75 and the unconjugated substrate being
eleased with the sulfate being replaced by a hydrogen abstracted
rom H290. In step III the pro-(R) hydroxyl of HFGS75 is depro-
onated by H136 and the ester bond is broken by attack of the
ctivated free hydroxyl. The sulfate is released and FG75 is regen-
rated. Release of the sulfate may  require an additional water
olecule as a nucleophile. This water may  accompany the incomingbons) and 3′-phosphoadenosine-5′-phosphosulfate (purple carbons) in the binding
n overlay of A and B, showing the short distance the sulfate has to move during the
substrate, shielding the charged sulfate during its passage into the
substrate binding site.
The reaction site lies at the base of a long narrow pocket that
opens beside the hydrophobic tail. This suggests that the substrate
and product may  have to travel through the endoplasmic reticulum
membrane in order to enter and leave the substrate binding site.
The binding site itself is formed predominantly from hydrophobic
residues (Fig. 12). The crystal structure has two  water molecules in
the substrate binding site, one of them putatively being the catalytic
water, but the other being a crystallographic water interacting with
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Fig. 6. The oestrogen sulfotransferase reaction mechanism. (A) The apoenzyme. (B) The enzyme-PAPS–substrate complex. (C) The intermediate. (D) The enzyme–PAP–product
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dapted from [52].
he sulfate of HFGS75. This second water has to be removed prior to
erforming docking experiments to determine how the substrate
nd product might ﬁt into the binding site.
Inhibition of steroid sulfatase (together with the inhibition of
romatase – see below) should reduce the amount of oestrogen
n the body, particularly in target tumour tissue, and be beneﬁcial
n a range of hormone-dependent diseases. The development of
teroid sulfatase inhibitors has been the subject of a number of
ecent reviews [62–66].
. 17-Hydroxysteroid dehydrogenasesThere are fourteen different vertebrate enzymes classiﬁed as
7-hydroxysteroid dehydrogenases of which twelve have been
ound in human tissues [67]. Despite their name the preferred sub-
trate of some of these enzymes is other than steroids and, whenthe substrate is a steroid, the reaction may  be either an oxidation
or a reduction depending on the cofactor and cellular localisa-
tion [68]. 17-Hydroxysteroid dehydrogenase type 1 (EC 1.1.1.62,
17-HSD1) catalyses the conversion of estrone to estradiol, and of
16-hydroxyestrone to estriol (Fig. 1). The reverse reactions are
catalysed by 17-HSD2 which also facilitates the conversion of
testosterone to androstenedione, the reverse reaction of which is
catalysed by 17-HSD3.
All three enzymes are members of the short-chain dehydroge-
nase/reductase (SDR) structural family. The aligned sequences are
shown in Fig. 13. Listed in Table 2 are the twenty-two publicly
available structures of 17-HSD1. Most of these structures have
a ligand in the substrate binding site: the structures of these lig-
ands are shown in Fig. 14. The gene can be translated into 328
amino acids but the mature protein has lost the initiating methio-
nine and, for historical reasons, is often (but not always) numbered
A1–Q327. Herein the A1–Q327 numbering is used. There are no
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<-- Sa->                    <H1>
1  MPLRKMKIPF LLLFFLWEAE SHAASRPNII LVMADDLGIG DPGCYGNKTI RTPNIDRLAS   60
<Sb>         <-- -H2  -->    <H3 >                             <--
61 GGVKLTQHLA ASPLCTPSRA AFMTGRYPVR SGMASWSRTG VFLFTASSGG LPTDEITFAK  120
-H4->  <Sc  ->                           <Sd>       <H5>        <--
121  LLKDQGYSTA LIGKWHLGMS CHSKTDFCHH PLHHGFNYFY GISLTNLRDC KPGEGSVFTT  18 0
-H6------ - ------ -H6- ---- ->        <------ - -H7------ - ------ -H7-
181  GFKRLVFLPL QIVGVTLLTL AALNCLGLLH VPLGVFFSLL FLAALILTLF LGFLHYFRPL  240
> <Se> <Sf->       < -------H8- ---->    < -Sg->
241  NCFMMRNYEI IQQPMSYDNL TQRLTVEAAQ FIQRNTETPF LLVLSYLHVH TALFSSKDFA  300
301  GKSQHGVYGD AVEEMDWSVG QILNLLDELR LANDTLIYFT SDQGAHVEEV SSKGEIHGGS  360
< Sh>         <Si>      <--- -H9-- - >
361  NGIYKGGKAN NWEGGIRVPG ILRWPRVIQA GQKIDEPTSN MDIFPTVAKL AGAPLPEDRI  42 0
<H10>           <-Sj->   <- -Sk->         <Sl >
421  IDGRDLMPLL EGKSQRSDHE FLFHYCNAYL NAVRWHPQNS TSIWKAFFFT PNFNPVGSNG  480
<Sm> <--- -H11  -------- ->
481  CFATHVCFCF GSYVTHHDPP LLFDISKDPR ERNPLTPASE PRFYEILKVM QEAADRHTQT  540
< H12>  <H13>
541  LPEVPDQFSW NNFLWKPWLQ LCCPSTGLSC QCDREKQDKR LSR                    583
Fig. 7. The sequence of steroid sulfatase (UniProt P08842). Residue C75 (highlighted) undergoes post-translational modiﬁcation to formylglycine [60].
Fig. 8. The three-dimensional structure of steroid sulfatase. PDB code 1P49 [59]. (A) A cartoon of the structure coloured blue at the N-terminus through to red at the C-
terminus. Residue HFGS75 and the calcium ion are in the middle of the structure. (B) The surface of the protein showing the hydrophobic nature of the membrane-embedded
tail  at the top.
Fig. 9. The structures of formylglycyl, hydroxyformylglycyl and hydroxyformylglycyl sulfate residues.
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Fig. 10. The interactions of the calcium ion and HFGS75 in the binding site of steroid
sulfatase. Hydrogen bonds involving HFGS75 are shown in orange. Interactions with
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Table 2
The crystal structures of 17-HSD1. No papers describing the 3DEY, 3KLP and 3KM0
structures have been published. The structures of the ligands are shown in Fig. 14.
PDB code Mutated
residues
Ligands Reference
1A27 – NADP, estradiol [69]
1BHS – – [70]
1DHT – 5-Dihydrotestosterone [71]
1EQU – NADP, equilin [72]
1FDS – Estradiol [73]
1FDT – NADP, estradiol [73]
1FDU H221L NADP, estradiol [74]
1FDV H221L NAD [74]
1FDW H221Q Estradiol [74]
1I5R – DHETNAa [75]
1IOL D112E Estradiol [76]
1JTV – Testosterone [77]
1QYV – NADP [78]
1QYW – NADP, 5-androstan-3,17-dione, [78]
1QYX – NADP, 4-androstene-3,17-dione [78]
3DEY – 5-Dihydrotestosterone –
3DHE – 3-Hydroxy-5-androsten-17-one [71]
3HB4 – E2Bb [79]
3HB5 – NADP, E2Bb [79]
3KLM – 5-Dihydrotestosterone [80]
3KLP – (3,8,17)-androst-5-ene-3,17-diol –
3KM0 – NADP, 5-androstan-3,17-diol –
a DHETNA: O5′-[9-(3,17-dihydroxy-1,3,5(10)-estratrien-16-yl)-
nonanoyl]adenosine.he calcium ion are shown in black, except for the interaction with HFGS75 which is
hown in blue. Based on the 1P49 structure [59]. (For interpretation of the references
o  colour in this ﬁgure legend, the reader is referred to the web  version of this article.)
ublicly available crystal structures of either 17-HSD2 or 17-
SD3, but the overall 3D structure of both is believed to be similar
o that of 17-HSD1 (Fig. 15).
The protein is built around a core of seven parallel -strands
ith at least one helix between successive strands. This makes
p the Rossman fold typical of nucleotide binding proteins. The
oop between sheet 1 and helix 1 has the GxxxGxG motif (residues
9–G15, where G is glycine and x any other residue) that is common
o oxidation/reduction enzymes that bind nicotinamide cofactors.
142, at the end of sheet 5, and Y155 and K159, in helix 9, have been
hown to be essential for activity [81].
Fig. 11. Proposed catalytic mechanism of steroid sulfatase.
dapted from [61].b E2B: 3-(((8R,9S,13S,14S,16R,17S)-3,17-dihydroxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-
yl)methyl)benzamide.
The substrate binding site is formed by residues G94, L95, L96,
S142, V143, G144, M147, L149, P150, N152, Y155, C185, G186,
P187, F192, M193, V196, Y218, H221, S222, V225, F226, F259, L262,
M279, E282 and V283. Of these twenty-six residues only fourteen
are in secondary structural elements, i.e.,  helices or sheets, with
the remainder being in loops between the structural elements.
One of these loops, the substrate binding loop comprising residues
H189–V196, is ﬂexible enough that it is observed in two conforma-
tions in the 1FDT structure. This loop probably has to move to allow
the substrate into the binding site. The following residues form the
NADPH binding site: T8, G9, C10, S11, S12, G13, I14, G15, R37, L64,
D65, V66, R67, C89, N90, A91, G92, L93, V113, T140, G141, S142,
Y155, K159, C185, V188, H189, T190, A191, F192, M193 and K195.
The hydride transfer reactions catalysed by these enzymes are
intrinsically reversible but, in vivo, are effectively unidirectional
due to the relative concentrations of NADPH and NADP+ [82].
Based on the measurement of isotope exchange rates between
substrate-product pairs the reaction catalysed by 17-HSD1 has
been reported to be a random order bi–bi mechanism [83] (Fig. 16).
However, a dynamics study based on crystal structures of the apo
enzyme and binary and ternary complexes has suggested that there
is a preferred order with NADPH binding before the substrate, and
the NADP+ being released before the product [84]. In the reaction
the pro-(S) hydride is transferred from NADPH to the alpha face
of the estrone C17. A hydride is then transferred to the C17 oxy-
gen, stabilised by interaction with the hydroxyl of S142, from the
hydroxyl of Y155. There is then postulated to be a hydride transfer
network involving the NADPH ribose hydroxyl, the K159 amino
moiety and a water molecule that results in the formation of a
hydronium ion [84] (Fig. 17). Work with the 17-HSD from the
ﬁlamentous fungus Cochliobolus lunatus has shown that cofactor
dissociation is the slowest step of the reaction and that the catalytic
activity might be modulated by differences in the conformation
of the substrate binding loop consequent upon cofactor and sub-
strate binding [85]. Enzymes of the SDR family are typically active as
dimers or tetramers, and work with the C. lunatus enzyme suggests
that dimerisation may  be necessary for activity [86].
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Fig. 12. The steroid sulfatase binding site. (A) The crystal structure of the steroid sulfatase substrate binding site. HFGS75 is shown with purple carbons. The calcium ion is
the  yellow sphere. The putative catalytic water is the red sphere. The brown sphere is the only other water present in the substrate binding site in the crystal structure. For
both  water molecules only the oxygen is shown. (B) Estrone docked into the substrate binding site of steroid sulfatase. The water in the substrate binding site was  removed
prior  to docking: it occupies the space taken by the estrone hydroxyl. (C) Estrone sulfate docked into the substrate binding site of steroid sulfatase. Prior to docking the sulfate
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cas  removed from residue 75 to leave hydroxyformylglycine. (D) An overlay of B a
o  move during the reaction. (For interpretation of the references to colour in this ﬁ
Of the estrogens estradiol is the most potent and the inhi-
ition of estradiol production is beneﬁcial in the treatment of
estrogen-dependent diseases. Inhibition of 17-HSD1 should pre-
ent estradiol production, though the concomitant inhibition of
romatase (see below) and steroid sulfatase is probably neces-
ary for greater reduction of estradiol levels. A variety of steroidal
nd non-steroidal inhibitors have been synthesised that have IC50
alues in the low nanomolar range. For recent reviews of these
nzymes and their inhibitors see [87–89].
. Aromatase (cytochrome P450 19A1, oestrogen synthase)
Aromatase (cytochrome P450 19A1, cytochrome P450AROM,
estrogen synthase) catalyzes the aromatisation of the ‘A’ ring of
ndrostendione to produce estrone and the aromatisation of the
A’ ring of testosterone to produce estradiol (Fig. 1). The enzyme
onsists of 503 amino acids (Fig. 18) and an iron-containing haemhowing the identical docked pose of the estrone core and how little the sulfate has
egend, the reader is referred to the web version of this article.)
group (protoporphyrin IX; Fig. 19). The protein is glycosylated on
N12 [90]. Other post-translational modiﬁcations are performed by
the tyrosine kinases c-Src [91] and PTP1B [92]: phosphorylation of
Y361 by c-Src increases aromatase activity. The enzyme is found
in the cytoplasm bound to the endoplasmic reticulum with the N-
terminal residues probably penetrating through the membrane and
the glycosylated residue in the lumen of the endoplasmic reticu-
lum. However, it has been suggested that the N-terminal residues
are required not so much for membrane association as for orienta-
tion [93]. There is evidence to suggest that aromatase forms dimers
or higher oligomers [93,94]. The proposed mode of oligomerisation
may  be a further means of regulating enzyme activity as it would
prevent the phosphorylation of Y361 [94].There are ﬁve publicly available crystal structures of human pla-
cental aromatase: PDB code 3EQM [95,96] has androstenedione in
the substrate binding site, as does 3S79 [97]; the inhibitor exemes-
tane (Fig. 19) is in the 3S7S structure [97]; the 4GL5 and 4GL7
M.P. Thomas, B.V.L. Potter / Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 27– 49 37
17β-HSD1                                                                  .
17β-HSD2    1  MSTFFSDTAW ICLAVPTVLC GTVFCKYKKS SGQLWSWMVC  LAGLCAVC LL   5 0
17β-HSD 3 1   MGDVLEQFFI  LTGLL.VC LA   1 9
. <Sa->       <--- -H1- .
17β-HSD1    1   M ART VVL ITGC SSGI GLHLAV   2 1
17β-HSD2   51   ILSPFWGLIL  FSVSC FLMYT YLSGQE LLPV DQK AVLVTGG D CGLGHALCK  10 0
17β-HSD3   20   CLAK...CVR  FSRCV LLNYW KVLPKS FLRS MGQWA VIT GA G DGI GKAYSF    66
. -->      <  -Sb-->  <H2>  <-- -H3-- ->       <- Sc>      <- .
17β-HSD1   22   RLASDPSQSF KVY ATLRDLK TQGRL WEAAR ALACPPGSLE TL QLDVRDS K 71
17β-HSD2  101   YLDE LGFTV. .FAG VLNENG P GAEELRRTC SPRLSV LQMD ITK.PVQI KD 14 7
17β-HSD3   67   ELAKRGLNVV LIS RTLEKLE A IATEIER TT GRSVKI IQAD FTK.D... .D 11 1
. –H4--- ->        < Sd>           <H5>    <--- - H6-- ->  <-- .
17β-HSD1   72  SVAAA RERVT EGRVD VLVCN AG.LGLLGPL  EAL.G EDAVA  SVL DVNVVGT 11 9
17β-HSD2  148   AYSKVAA MLQ DRGLWAV INN AGVLGFPTDG  ELLLM TDYKQ CMA .VNFFGT 19 6
17β-HSD3  112   IYEHI KEKLA GLEIG ILVN N VGMLPNLLPS H FLNA PDEIQ SLIH CNITS V 16 1
. --- -H7--- - -- ->  < Se>     <H8>        <---- - -H9------ - .
17β-HSD1  120   VRMLQAFL PD MKRRGS GRVL VTGSVGGLMG LPFNDVYCAS KFALEGLCE S 16 9
17β-HSD2  197   VEVTKTFL PL LR.K SKG RLV  NVSSMGGGAP MERLA SYGSS KAA VTMFSSV 24 5
17β-HSD3  162   VKMT QLILKH  MESRQKGLIL NISSGI ALFP WPLYS MYSAS KAFVCAFSKA 21 1
. -- -H9--> < --Sf-->          <H10>     <-H1 1- >   <--H1 2- .
17β-HSD1  170   LAV LLLP FGV HLS LIECGPV HTAF...MEK VLGSPEE VLD RTDIHTFHR F 21 6
17β-HSD2  246  MR LELSK WGI KVA SIQPGGF  LTNIAGTS DK WEKLEKD ILD HLPA EVQED Y 29 5
17β-HSD3  212   LQEEYKAK EV IIQVLTPY AV STAMT..... ...... ...K  YLNT NVITKT  24 7
. -- -- -H1 2- --- ->    <- -- -H1 3--- - >         < Sg>      <- .
17β-HSD1  217   YQ.YLAHSKQ  VFREAAQNPE EVAEV FLTAL RAP KPT...L  RYFTTE RFLP  26 2
17β-HSD2  296   GQDYILAQ RN FLLLINSLAS KDFSP VLRDI QHAI LAKSPF  AYY TPG KGAY  34 5
17β-HSD3   248  ADEFVK ESLN YVTIGGETCG CLAHE ILAGF LSL IPA...W  AFYS.. .GAF  29 1
. –H14>        <-- -H1 5-- ->                                   .
17β-HSD1  263   LLRMRLDDPS GS NYVTAMHR EVFGDVPAKA EAGAEAGGGA GPGAEDEAGR  31 2
17β-HSD2  346   LWI CLAHYLP IG IYDYFA KR HF GQDKPMPR ALRMPNYKKK AT          38 7
17β-HSD3  292  QRL LLTHYVA YLKL NTKVR                                    31 0
. .
17β-HSD1  313  GAVGDPELGD PPAAPQ                                       32 8
17β-HSD2                                                                  .
17β-HSD3                                                                  .
Fig. 13. Sequence alignment of 17-hydroxysteroid dehydrogenases. An alignment of the 17-HSD1 (UniProt ID code P14061), 17-HSD2 (UniProt ID code P37059) and
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A7-HSD3  (UniProt ID code P37058) sequences. Identical residues are highlighted i
isual  inspection of the structure, are shown in bold, and those forming the NADPH
s  H – helix and S – sheet. (For interpretation of the references to colour in this ﬁgu
tructures [97] both have O-linked alkyne chains attached to the
-position of the steroid ring. All ﬁve structures are of residues
45–N496. They reveal a predominantly helical single domain pro-
ein with the ligand tightly enclosed in a largely hydrophobic
ocket, situated deep within the protein, that is formed by residues
115, I133, F134, F221, W224, E302, I305, A306, D309, T310, V369,
370, L372, V373, M374, L477 and S478, and the haem (Fig. 20).
here is a hydrogen bond between the backbone NH of M374 and
he ligand carbonyl at the 17-position and another between the
ide chain of D309 and the ligand carbonyl at the 3-position. In the
EQM and 3S79 structures the androstenedione has an identical
ose, as do the haems and the residues forming the binding site.
he B, C and D rings of exemestane overlay the equivalent rings in
ndrostenedione but, because of the additional double bond in the
 ring of exemestane, the A ring is slightly distorted relative to thew. Those residues in 17-HSD1 forming the substrate binding site, as identiﬁed by
ng site are shown in red. Secondary structure elements in 17-HSD1 are identiﬁed
end, the reader is referred to the web  version of this article.)
androstenedione A ring. The C6-methylidene carbon is accommo-
dated by slight shifts (less than 1 A˚) in the position of T310 and, to a
lesser extent, S478. Despite the greater size of the 6-substituent in
the 4GL5 and 4GL7 structures there is no further signiﬁcant move-
ment of any of the amino acid residues in the substrate binding
site.
The aromatisation occurs in a three-step mechanism [98,99]
(Fig. 21). Two consecutive hydroxylations generate, ﬁrst, a hydroxyl
at C19 and, second, a gem-diol intermediate that dehydrates to
leave an aldehyde [100]. The ketone at the 3-position then enolises
and the aldehyde is cleaved from C10 and ejected as methanoic
(formic) acid [101]. This implies that the aromatase catalytic cen-
tre can catalyse two  different types of reaction (Eqs. (1) and (2)).
Note that the ﬁrst hydroxylation of C19, whilst leaving the absolute
conﬁguration of C10 unchanged, does change the stereochemistry
of C10 from R to S.
(1)(2)
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Fig. 14. The structures of the ligands in the crystal structures of 17-HSD1. DHETNA: O5′-[9-(3,17-dihydroxy-1,3,5(10)-estratrien-16-yl)-nonanoyl]adenosine. E2B:
3-(((8R,9S,13S,14S,16R,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)methyl)benzamide.
Fig. 15. The structure of 17-HSD1. A cartoon of the 17-HSD1 structure coloured blue at the N-terminus through to red at the C-terminus. The secondary structure elements
are  labelled as in Fig. 13: H – helix and S – sheet. NADPH is shown with purple carbons and estradiol with pink carbons (based on the 1A27 structure [69]). (For interpretation
of  the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 16. The proposed random order bi–bi mechanism of 17-HSD1. The mechanism believed to be preferred is shown in bold [83,84]. E – enzyme, E1 – estrone, E2 – estradiol.
Fig. 17. The substrate binding site of 17-HSD1. The nucleotide binding GxxxGxG motif and the residues involved in catalysis are shown in green. The NADPH is in purple
and  the estradiol in pink. Secondary structure elements are shown in grey. Some of the possible hydrogen bonds are shown by the black dashed lines. (For interpretation of
the  references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
<--- -
1  MVLEMLNPIH YNITSIVPEA MPAATMPVLL LTGLFLLVWN YEGTSSIPGP GYCMGIGPLI   6 0
-H1----->< ----H2---- >  <-Sa>     <-Sb> <- --H3---><- H4>    <--
61  SHGRFLWMGI GSACNYYNRV YGEFMRVWIS GEETLIISKS SSMFHIMKHN HYSSRFGSKL  120
-H5-->            <-- - -- -H6---- - ->  <--- -H7 --------- - -H7--- ->
121  GLQCIGMHEK GIIFNNNPEL WKTTRPFFMK ALSGPGLVRM VTVCAESLKT HLDRLEEVTN  180
<--H8  ------- -H8  -- ->     <- --H9----- - -H9-- ->     <--H1 0-><-
181  ESGYVDVLTL LRRVMLDTSN TLFLRIPLDE SAIVVKIQGY FDAWQALLIK PDIFFKISWL  240
-H11------ --H11----- ---H11->   <H12> <--- -H13--->    <---H14--
241  YKKYEKSVKD LKDAIEVLIA EKRRRISTEE KLEECMDFAT ELILAEKRGD LTRENVNQCI  300
--H14----- ------H14- ---><----- -H15------ >    <H16>   <---H17-
301  LEMLIAAPDT MSVSLFFMLF LIAKHPNVEE AIIKEIQTVI GERDIKIDDI QKLKVMENFI  36 0
--H17->      <Sc>    <Sd> <Se> <Sf><--- H18->
361  YESMRYQPVV DLVMRKALED DVIDGYPVKK GTNIILNIGR MHRLEFFPKP NEFTLENFAK  420
<- -H19------ -H19-> <Sg ->          <Sh>  <Si
421  NVPYRYFQPF GFGPRGCAGK YIAMVMMKAI LVTLLRRFHV KTLQGQCVES IQKIHDLSLH  48 0
>        < -Sj>
481  PDETKNMLEM IFTPRNSDRC LEH                                          503
Fig. 18. The sequence of aromatase (UniProt ID code P11511). H – helix and S – sheet.
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kets. One face of the ligand is bordered by I117 (V126), T118 (S127),ig. 19. The structure of ligands in the aromatase binding site. The protoporphyrin
s  in all the crystal structures of aromatase.
Residues involved in the catalytic act probably include A306,
309 and T310. The binding site opens to the ER membrane so
he substrate has to traverse the membrane in order to enter the
inding site. NADPH does not bind directly to aromatase. Two  elec-
rons are transferred from NADPH to the aromatase haem group
ia NADPH cytochrome P450 reductase, an FAD/FMN-containing
rotein [102,103].
Atomic force microscopy has been used to observe aromatase
imers in membranes, and possibly higher order interactions [93].
omputational modelling of aromatase in membranes suggests
hat a dynamic quaternary organisation together with ﬂuctuations
f the active site, the cavity enclosing the haem and the substrate
ccess channel are necessary for activity [104,105].
The inhibition of aromatase is a suitable treatment for a num-
er of clinical conditions that are caused or aggravated by the
verproduction of oestrogen. Aromatase inhibitors such as anas-
rozole, letrozole and exemestane (Fig. 22) have found roles
n the treatment of breast cancer [106], ovarian cancer [107]
nd growth maximisation in puberty in children with short
tature [108], and it has been suggested that aromatase inhibitors
ay  have a role to play in treating some cases of lung cancer
109].
. Enzymes of steroid hydroxylation
Aromatase, cytochrome P450 19A1, catalyzes the hydroxylation
f testosterone and androstenedione at C19 prior to aromatising the
-ring. Other cytochrome P450s catalyse hydroxylations at other
ites [110], most commonly the 2-, 4- and 16-positions. It has been
rgued that which cytochrome is involved with which hydrox-
lation is dependent on both the body tissue and the substrate
oncentration [111].Fig. 20. The aromatase substrate binding site. (A) The haem-capped cavity tightly
enclosing androstenedione. (B) The residues forming the substrate binding site.
Cytochrome P450s 1A1, 2C19, 3A4 and 3A5 are amongst those
reported to catalyse hydroxylation at the 16-position [111,112].
This generates 16-hydroxyestrone which can then be converted
to estriol by 17-HSD1. Reported to be involved in both 2- and 4-
hydroxylations are cytochrome P450s 1A1, 1A2 and 1B1, though
the relative importance of these might depend upon the tissue,
and others are probably involved [111]. In the PDB are the struc-
tures of more than 500 cytochrome P450s, over 100 of which are
of human proteins. The structures of CYPs 1A2, 1B1 and 3A4 are
brieﬂy discussed herein.
There is one crystal structure of human CYP 1A2, PDB code 2HI4
[113], and one of CYP 1B1, PDB code 3PM0 [114]. The structure
of both is based on that of the canonical P450 fold – twelve -
helices and four -sheets, designated A-L and 1–4, respectively –
with a few additional helices. Both have the same haem group, pro-
toporphyrin IX, as that in aromatase (Fig. 19). In both enzymes the
substrate binding site is a narrow pocket that tightly encloses a
molecule of -naphthoﬂavone, with many of the residues forming
the binding sites being the same in the two proteins. In the follow-
ing listing of these residues the numbers for CYP 1A2 are given ﬁrst,
with the numbers for the equivalent residues in CYP 1B1 in brac-S122 (S131), T124 (A133), F125 (F134), T223 (N228), F226 (F231),
V227 (G232), F256 (L264), N257 (N265), L382 (V395), T385 (T398),
I386 (I399), L497 (L509) and T498 (T510). F226 (F231) forms a
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Carbons 3, 10 and 19 are identiﬁed as is the stereochemistry of C10.
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Table 3
The crystal structures of cytochrome P450 3A4. The structures of the ligands are
shown in Fig. 22.
PDB code Ligands Reference
1TQN – [115]
1W0E – [116]
1W0F Progesteronea [116]
1W0G Metyrapone [116]
2J0D Erythromycin A [117]
2V0M Ketoconazoleb [117]
3NXU Ritonavir [118]
3TJS Desthiazolylmethyloxycarbonyl ritonavir [119]Fig. 21. The mechanism of the aromatase-catalysed reaction. 
ace-to-face – stacking interaction with the ligand. The other
ace of the ligand is contacted by V220 (L225), F260 (F268), N312
T325), D313 (D326), F315 (F328), G316 (G329), A317 (A330), F319
Q332), D320 (D333) and T321 (T334).
Since both enzymes can hydroxylate estrone at either the 2-
r 4-position there must be sufﬁcient ﬂexibility in the substrate
inding site, despite the restrictiveness observed in the crystal
tructures, to allow the substrate to bind in different poses to
resent either the 2- or 4-positions to the catalytic centre. That
uch ﬂexibility of substrate binding exists is demonstrated by the
act that the pose of the -naphthoﬂavone in one structure is the
pposite way round to that in the other structure (Fig. 23).
There are nine publicly available structures of CYP 3A4 (Table 3).
his enzyme catalyzes hydroxylation at the 16-position. In the
arious structures there are seven different structurally diverse
3UA1 Bromoergocryptine [120]
a The progesterone is not in the substrate binding site, but in a groove on the
surface of the protein.
b There are two molecules of ketoconazole in the substrate binding site.
Fig. 22. The structure of some clinically used aromatase inhibitors.
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Fig. 23. CYP 1A2 and CYP 1B1 substrate binding site structures. Overlay of CYP 1A2 (PDB code 2HI4 [113]) and CYP 1B1 (PDB code 3PM0 [114]) demonstrating the similarity
of  the residues forming the substrate binding site and the different pose of the bound ligand, -naphthoﬂavone. To avoid obscuring the ligand residues in the foreground are
shown as lines rather than sticks. CYP 1A2 – green protein/haem, yellow ligand. CYP 1B1 – blue protein/haem, purple ligand. (For interpretation of the references to colour
in  this ﬁgure legend, the reader is referred to the web  version of this article.)
Fig. 24. The structures of the ligands in the crystal structures of cytochrome P450 3A4.
M.P. Thomas, B.V.L. Potter / Journal of Steroid Biochem
Fig. 25. The CYP450 3A4 substrate binding site. (A) Ritonavir in the substrate binding
site of CYP450 3A4. Taken from the 3NXU crystal structure [118]. (B) The variability
in  the shape of the substrate binding site. All nine structures are superimposed
and equivalent residues coloured the same. The haem and ritonavir from the 3NXU
s
c
i
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d
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1tructure are shown. In both ﬁgures the haem is shown in purple and the ritonavir in
yan. (For interpretation of the references to colour in this ﬁgure legend, the reader
s  referred to the web version of this article.)
igands (Fig. 24), though one of these, progesterone, is not in the
ubstrate binding site but in a groove on the surface. To accommo-
ate these ligands there is considerable variability in the shape of
he substrate binding site (Fig. 25). This variability shows that there
s plenty of space to accommodate estrone such that it presents the
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8. Catechol O-methyl transferase (COMT)
The 2- and 4-hydroxy groups on the oestrogen A ring can be
converted to methoxy groups by catechol O-methyl transferase
(COMT; EC 2.1.1.6; reviewed in [121]) though it should be noted
that hydroxylation and ketonisation of estrogens is not limited to
these positions: Zhu and Conney [122] list hydroxylations at the 1-,
2-, 4-, 6-, 7-, 11-, 14-, 15-, 16-, 17- and 18-positions. This enzyme
is regarded as a phase II drug metabolising enzyme that catalyzes
a detoxifying step in drug metabolism [123]. Hydroxylation and
methylation are the ﬁrst steps in the oestrogen degradative and
excretory pathways, though the hydroxylated and methoxylated
compounds may have roles beyond being mere waste products:
see, e.g., [124].
COMT exists in two forms, soluble (s-COMT, 221 residues) and
membrane bound (mb-COMT, 271 residues) that differ only in the
presence of an additional ﬁfty residues at the N-terminal end of
the membrane-bound form (Fig. 26). The residue numbering for
s-COMT, 1–221, will be used herein. Residue 108 is a site of a com-
mon polymorphism: it can be either valine or methionine. The rarer
methionine polymorphism has been associated with a variety of
neuropsychiatric disorders [125], increased risk of breast cancer
[126,127], lower pain threshold [128] and improved cognitive func-
tion involving working memory [129]. These different effects of the
polymorphs may  be due to the slightly greater enzyme activity of
the valine variant [130–132] and/or the greater range of confor-
mational states of the methionine variant observed in molecular
dynamics simulations [133] that were suggested by the greater
instability (with respect to temperature, autoxidation and denat-
urants) of the methionine variant (see, e.g., [134] and references
therein).
There are three crystal structures of human s-COMT, one of
which is of the methionine variant (3BWY; [135]) and the oth-
ers of the valine variant (3BWM;  [136]: 3A7E; unpublished). All
three have the methyl group donor, S-adenosyl methionine (SAM),
and an inhibitor, 3,5-dinitrocatechol (DNC), bound (Fig. 27). The
structure of s-COMT is one of two  sets of -helices sandwiching a
seven-stranded -sheet core (Fig. 28). A shallow cleft on the pro-
tein surface is occupied by SAM, DNC and a magnesium ion. The
SAM binding pocket has a base formed by the C-terminal ends of
-sheets a–d with the walls of the pocket formed by helix 6 and
the loops between helix 2 and helix 3, -sheet a and helix 4, and -
sheet d and helix 7. The SAM methyl group is directed towards the
substrate binding site and the catechol oxygen to be methylated.
The methylation reaction is dependent on an initial strict
sequential order of reactant binding. SAM binding is followed by
the binding of a magnesium ion which is followed by the cate-
chol entering the binding site [130,136]. This order is necessary
because the binding of one changes the shape of the binding site
so that the next can bind. If reactant binding does not occur in this
order a dead-end complex is formed. The magnesium ion is held
in place by coordination with three acidic residues, D141, D169
and E199 the latter two of which are oriented by interaction with
K46 (Fig. 29). The oxygen acting as the methyl recipient is acti-
vated by K144 which acts as a general base in the methylation.
In a direct bimolecular transfer the SAM methyl group is trans-
ferred from the sulphur to the catechol hydroxyl oxygen through
an SN2-like transition state [137].
COMT inhibitors have been developed primarily for the treat-
ment of Parkinson’s disease [138,139].9. Discussion
Sulfotransferase, sulfatase, 17-HSD1 and aromatase all have
to recognise estrone (as either a substrate or a product of the
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1   (-) MPEAPPLLLA AVLLGLVLLV VLLLLLRHWG WGLCLIGWNE FILQPIHNL L 50    (-)
<--H1- ---- ->       <----- -H2  ---- ->         <--H3--
51   (1) MGDTKEQRIL NHVLQHAEPG NAQSVLEAID TYCEQKEWAM NVGDKKGKI V 100  (50 )
--H3-->     <-Sa>      <-- -H4-- ->      <-Sb->     <-- -H5--
101   (51)  DAVIQEHQPS VLLELGAYCG  YSAVRMARLL SPGARL ITIE INPDCAAIT Q 150 (100 )
-H5-->  <-Sc>  <- ---H6---->       <Sd>    <--H7--
151 (101 ) RMVDFA GVKD KVTLVVGASQ DIIPQLKKKY  DVDTLDMVFL DHWKDRYLP D 200 (150 )
--H7-->       <--Se->         <-- - H8-->    <- -Sf->                 
201 (151) TLLLEECGLL RKGTVLLADN VICPGAPDFL AHVRGSSCFE CTHYQSFLEY 250 (200)
<--Sg  ->                                              .
251 (201 ) REVVDGLEKA IYKGPGSEAG P                                 27 1 (221 )
Fig. 26. The sequence of human COMT. UniProt ID code P21964. The ﬁfty residues present in mb-COMT but absent in s-COMT are shown in italics. The residue numbering,
1-271,  is for mb-COMT: s-COMT is numbered 1–221 (shown in brackets) starting from residue 51 of mb-COMT. Highlighted is residue 158 (mb-COMT) or 108 (s-COMT) that
is  the site of a V/M polymorphism. Secondary structure elements are labelled: H – helix; S – sheet.
ture o
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rFig. 27. Ligands in the crystal structures of COMT. (A) The struc
atalysed reaction) and at least one other steroid. Despite this
ommon recognition requirement there is no structural similarity
etween the four proteins in terms of the secondary and tertiary
tructure and little similarity in the structure of the oestrogen
ig. 28. The structure of s-COMT. A cartoon of the s-COMT structure coloured blue at
he  N-terminus through to red at the C-terminus. The secondary structure elements
re labelled as in Fig. 27: H – helix and S – sheet. SAM and DNC are shown with purple
arbons. The yellow sphere is a magnesium ion. Based on the 3BWM structure [136].
For interpretation of the references to colour in this ﬁgure legend, the reader is
eferred to the web  version of this article.)f S-adenosyl methionine (SAM). (B) 3,5-dinitrocatechol (DNC).
binding sites (Fig. 30). The possible exception to this assertion is,
perhaps unsurprisingly given that they catalyse opposite reactions,
sulfatase and sulfotransferase. These two enzymes both have a ﬂat
surface against which the substrate A and B rings can nestle. This
ﬂat surface is formed by L103 in sulfatase and V145 in sulfotrans-
ferase (Fig. 31). Both enzymes also have a histidine and two lysines
adjacent to the cofactor sulfate group – H136, K134 and K368 in
sulfatase, and H107, K47 and K105 in sulfotransferase – possibly
suggesting some degree of similarity in the mechanism of the sul-
fate transfer reactions.
Since estrogens have an important role to play in hormone-
dependent cancers the inhibition of the enzymes responsible for
producing estrogens is equally important. Historically, most effort
has been focused on the development of aromatase and sulfatase
inhibitors [140], but more recently considerable effort has been
put into the development of 17-HSD1 inhibitors [87–89]. Aro-
matase is the only enzyme capable of aromatising the ‘A’ ring thus
converting androgens to estrogens. The inhibition of aromatase
will, therefore, prevent oestrogen production. However, stores of
estrone sulfate (accumulated from the circulation throughout the
body at higher levels in breast cancer tissue than normal tissue
[141,142]) can be converted to estrone by sulfatase and then to
estradiol by 17-HSD1. With levels of sulfatase and 17-HSD1
being higher in cancerous tissue than non-cancerous tissue this has
been reported to be the main route of oestrogen production in can-
cerous breast tissue [143–145; see, also, 146] which might suggest
that the inhibition of aromatase alone would be unlikely to be a
successful treatment in more than a minority of cases. However,
aromatase inhibitors such as letrozole, anastrozole and exemes-
tane have proven to be highly effective treatments for many breast
cancers [106].
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Fig. 29. The COMT substrate binding site. SAM is shown with purple carbons, DNC with cyan carbons. Five amino acid side chains are shown with green carbons. The
interaction of K144 with a potential substrate is shown by the orange dashed line. Interactions between three acid groups (D141, D169 and E199) and the metal ion are
shown by the black dashed lines. The interactions of D169 and E199 with K46 are shown by the pink dashed lines. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 30. Structure comparison of four oestrogen binding proteins. Shown with estrone (cyan) in the substrate binding site and in the same orientation: (A) aromatase (haem
in  purple); (B) 17-HSD1 (NADP in purple); (C) sulfotransferase (PAPS in purple); (D) sulfatase (HFGS75 in purple). (For interpretation of the references to colour in this
ﬁgure  legend, the reader is referred to the web version of this article.)
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Fig. 31. Overlay of the sulfotransferase and sulfatase oestrogen binding sites.
Comparison of sulfotransferase (protein: pink carbons, PAPS: purple carbons) and
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and potential clinical applications, Climacteric 11 (Suppl. 1) (2008) 47–58,ulfatase (protein: light green carbons, HFGS75: dark green carbons). Estrone is
hown with cyan carbons. (For interpretation of the references to colour in this
gure legend, the reader is referred to the web  version of this article.)
The different binding site structures of the various oestro-
en metabolising enzymes mean that speciﬁc inhibitors can be
esigned. A more recent approach, however, is to design molecules
hat inhibit multiple drug targets, and the ﬁrst reports of single
olecule dual aromatase-sulfatase inhibitors have been published
147–149]. Inhibitors of other combinations of enzymes are feasible
nd the development of these will be facilitated by structure-based
esign. Inhibition of aromatase already reduces circulating levels
f estradiol to below detectable levels. The concurrent inhibition
f sulfatase and also, perhaps, 17-HSD1 should cut the localised
n situ production of estradiol in tumour tissue. By inhibiting aro-
atase, sulfatase and 17-HSD1 all oestrogen production should be
topped. This may, however, have adverse consequences as estro-
ens are known to have protective effects on the heart [150]: the
ncidence of cardiovascular disease in postmenopausal women is
hree times that of premenopausal women of the same age [151].
his is due, at least in part, to the increased level of aldosterone
152] which is synthesised by CYP11B2 (aldosterone synthase). The
imultaneous inhibition of CYP19 (aromatase) and CYP11B2 should
educe the levels of both oestrogen and aldosterone thus having
he desired anti-cancer and anti-cardiovascular disease effects. The
rst dual inhibitors of CYP19 and CYP11B2 have recently been
eported [8].
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